All In Biotech

Drug Trial Radar · NCT07556796

Study of IBI3016 in People With Mild or Moderate Hypertension Patients

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Features of a Single Subcutaneous Administration of IBI3016 in Patients With Mild or Moderate Hypertension in China

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

May 8, 2026

Primary completion

Oct 16, 2027

Study completion Oct 16, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Chinese patients with mild to moderate hypertension.

Conditions

  • Hypertension

Interventions

  • IBI3016Drug

    Solution of Injection

  • PlaceboOther

    0.9% sodium chloride saline solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety indicators-Number of Participants with Adverse Events (AEs)Time frame: from baseline to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.